Search Medical Condition
Please enter condition
Please choose location

Leland, North Carolina Clinical Trials

A listing of Leland, North Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (104) clinical trials

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

This is a prospective, noninterventional (no treatment medication provided by the study), observational (study in which the investigators/ physicians observe the patients and measure their outcomes), multicenter (study conducted at multiple sites) study of Golimumab IV and Infliximab in RA patients. The study allows for an anticipated 2-year enrollment period ...

Phase N/A

0.0 miles

Learn More »

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ) Compared to Placebo and Adalimumab in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who have responded inadequately to MTX. The primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce the disease activity and ...

Phase

0.0 miles

Learn More »

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo and versus adalimumab every other week (eow) in participants with moderately to severely active Psoriatic ...

Phase

0.0 miles

Learn More »

A research study is evaluating an investigational medication for hot flashes (vasomotor symptoms) in menopausal or postmenopausal women. Qualified participants will receive all study-related care and study medication or placebo at no cost. Financial compensation may be provided for time and travel expenses.  

Phase N/A

4.77 miles

Learn More »

Belimumab (BENLYSTA ) Pregnancy Registry

This global Belimumab Pregnancy Registry will collect prospective data on pregnancies and pregnancy outcomes on a voluntary basis in women with systemic lupus erythematosus (SLE) who have received commercially supplied belimumab within the 4 months prior to and/or during pregnancy. The registry will also evaluate outcomes of infants born to ...

Phase N/A

4.77 miles

Learn More »

C. difficile (C. diff) is one of the most common causes of healthcare-related infections. C. diff is a type of bacteria that lives in the human intestines and its spores can survive outside of the body for months. These spores are resistant to cleaning and are most commonly transmitted in ...

Phase N/A

4.77 miles

Learn More »

A research study is evaluating an investigational medication for type 2 diabetes in patients who have moderate kidney impairment.  

Phase N/A

4.77 miles

Learn More »

Fluarix / FluLaval / Fluarix Quadrivalent/ FluLaval Quadrivalent Vaccine Pregnancy Registry

This study is a transition of existing ongoing pregnancy registries for Fluarix/ FluLaval/Fluarix Quadrivalent/ FluLaval Quadrivalent into one post-authorization safety study (PASS). Pregnancy outcome data will be collected using questionnaires within 3 months of the estimated date of delivery (EDD) and approximately 6 months and 12 months after the EDD ...

Phase N/A

6.6 miles

Learn More »

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry

The Novartis Meningococcal quadrivalent CRM-197 conjugate vaccine pregnancy registry is stablished to meet a post marketing commitment agreed upon with CBER to prospectively collect data on pregnancy exposures to Novartis Meningococcal quadrivalent CRM-197 conjugate vaccine. It is an observational study of women inadvertently immunized with the Novartis Meningococcal quadrivalent CRM-197 ...

Phase N/A

6.6 miles

Learn More »

Safety of 4CMenB Exposure During Pregnancy

4CMenB was approved by the Food and Drug Administration (FDA) in the United States in January 2015 for people aged 10 through 25 years of age. 4CMenB should be used during pregnancy only if clearly needed and sometimes, inadvertent exposure during pregnancy may also occur - before the woman knows ...

Phase N/A

6.6 miles

Learn More »